Inventiva to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference 6 March 2019
The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI 5 March 2019
Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI 3 January 2018
Inventiva’s Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the European Medicines Agency 29 August 2017
Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference 29 June 2017
